series-c-plus
Stage
2017
Founded
5
Investors
About
GNA Biosolutions develops molecular diagnostic technologies, including the GNA Neo rapid diagnostic system that can test up to eight samples simultaneously near the point of care. Its platform has been used with more than 30 assays for research and diagnostics, including MRSA, tuberculosis, Ebola and plague.
Explore GNA Biosolutions's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.